Skip to main content
SpringerLink
Log in

Establishing a Program for Young Women at High Risk for Breast Cancer

  • Chapter
  • First Online:
Breast Cancer in Young Women

  • 828 Accesses

Abstract

Based on current evidence, high-risk individuals require different screening and risk reduction strategies from those deployed for the population at large. Potential benefits of specialized programs for women with high breast cancer risk include more cost-effective interventions as a result of patient stratification on the basis of risk and gathering a prospective registry with data coordinators in the team that can be directed to further improvements in patient care.

Each high-risk program needs to be designed by its institution with consideration of local resources and country legislation, especially related to genetic issues. Development of a successful high-risk program includes identifying strengths, weaknesses, opportunities, and threats, developing a promotion plan, choosing a risk assessment tool, defining “high risk,” and planning screening and risk reduction strategies for the specific population served by the program.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. https://cancerstatisticscenter.cancer.org.

  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.

    Article  PubMed  Google Scholar 

  3. Litton JK, Eralp Y, Gonzalez-Angulo AM, Broglio K, Uyei A, Hortobagyi GN, et al. Multifocal breast cancer in women < or =35 years old. Cancer. 2007;110(7):1445–50.

    Article  PubMed  Google Scholar 

  4. Clamp A, Danson S, Clemons M. Hormonal risk factors for breast cancer: identification, chemoprevention, and other intervention strategies. Lancet Oncol. 2002;3(10):611–9.

    Article  CAS  PubMed  Google Scholar 

  5. Collaborative Group on Hormonal Factors in Breast Cancer. Menarche m, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol. 2012;13(11):1141–51.

    Article  PubMed Central  Google Scholar 

  6. Cadeau C, Fournier A, Mesrine S, et al. Postmenopausal breast cancer risk and interactions between body mass index, menopausal hormone therapy use, and vitamin D supplementation: Evidence from the E3N cohort. Int J Cancer. 2016;139(10):2193–200.

    Google Scholar 

  7. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33.

    Article  CAS  PubMed  Google Scholar 

  8. Travis R, Key T. Oestrogen exposure and breast cancer risk. Breast Cancer Res. 2003;5(5):239–247.

    Google Scholar 

  9. Hilakivi-Clarke L, de Assis S, Warri A. Exposures to synthetic estrogens at different times during the life, and their effect on breast cancer risk. J Mammary Gland Biol Neoplasia. 2013;18:25–42.

    Article  PubMed  PubMed Central  Google Scholar 

  10. World Cancer Research Fund/American Institute for Cancer Research. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington, DC: AICR; 2007. http://www.wcrf.org/int/research-we-fund/continuous-update-project-cup/second-expert-report

  11. Travis RC, Key TJ. Oestrogen exposure and breast cancer risk. Breast Cancer Res. 2003;5(5):239–47.

    Google Scholar 

  12. Henderson TO, Amsterdam A, Bhatia S, Hudson MM, Meadows AT, Neglia JP, et al. Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer. Ann Intern Med. 2010;152(7):444–55. W144–54

    Article  PubMed  PubMed Central  Google Scholar 

  13. Guibout C, Adjadj E, Rubino C, Shamsaldin A, Grimaud E, Hawkins M, et al. Malignant breast tumors after radiotherapy for a first cancer during childhood. J ClinOncol. 2005;23(1):197–204.

    Article  Google Scholar 

  14. Preston DL, Cullings H, Suyama A, et al. Solid cancer incidence in atomic bomb survivors exposed in utero or as young children. J Natl Cancer Inst. 2008;100:428–36.

    Article  PubMed  Google Scholar 

  15. Pukkala E, Kesminiene A, Poliakov S, et al. Breast cancer in Belarus and Ukraine after the Chernobyl accident. Int J Cancer. 2006;119:651–8.

    Article  CAS  PubMed  Google Scholar 

  16. Barlow WE, White E, Ballard-Barbash R, Vacek PM, Titus-Ernstoff L, Carney PA, et al. Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst. 2006;98(17):1204–14.

    Article  PubMed  Google Scholar 

  17. Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med. 2007;356(3):227–36.

    Article  CAS  PubMed  Google Scholar 

  18. McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer EpidemiolBiomarkPrev. 2006;15:1159–69.

    Google Scholar 

  19. Pettersson A, Hankinson SE, Willett WC, Lagiou P, Trichopoulos D, Tamimi RM. Nondense mammographic area and risk of breast cancer. Breast Cancer Res. 2011;13(5):R100.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Rauh C, Hack CC, Häberle L, Hein A, Engel A, Schrauder MG, et al. Percent mammographic density and dense area as risk factors for breast cancer. GeburtshilfeFrauenheilkd. 2012;72:727–33.

    CAS  Google Scholar 

  21. Cote ML, Ruterbusch JJ, Alosh B, Bandyopadhyay S, Kim E, Albashiti B, et al. Benign breast disease and the risk of subsequent breast cancer in African American women. Cancer Prev Res (Phila). 2012;5(12):1375–80.

    Article  Google Scholar 

  22. Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, et al. Benign breast disease and the risk of breast cancer. N Engl J Med. 2005;353(3):229–37.

    Article  CAS  PubMed  Google Scholar 

  23. Dupont WD, Parl FF, Hartmann WH, Brinton LA, Winfield AC, Worrell JA, et al. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer. 1993;71(4):1258–65.

    Article  CAS  PubMed  Google Scholar 

  24. Ward EM, De Santis CE, Lin CC, Kramer JL, Jemal A, Kohler B, et al. Cancer statistics: Breast cancer in situ. CA Cancer J Clin. 2015;65(6):481–95.

    Article  PubMed  Google Scholar 

  25. Kerlikowske K. Epidemiology of ductal carcinoma in situ. J Natl Cancer Inst Monogr. 2010;2010(41):139–41.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Welch HG, Black WC. Using autopsy series to estimate the disease “reservoir” for ductal carcinoma in situ of the breast: how much more breast cancer can we find? Ann Intern Med. 1997;127:1023–8.

    Article  CAS  PubMed  Google Scholar 

  27. Collins LC, Tamimi RM, Baer HJ, Connolly JL, Colditz GA, Schnitt SJ. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses’ Health Study. Cancer. 2005;103(9):1778–84.

    Article  PubMed  Google Scholar 

  28. Erbas B, Provenzano E, Armes J, Gertig D. The natural history of ductal carcinoma in situ of the breast: a review. Breast Cancer Res Treat. 2006;97(2):135–44.

    Article  PubMed  Google Scholar 

  29. Sanders ME, Schuyler PA, Simpson JF, Page DL, Dupont WD. Continued observation of the natural history of low-grade ductal carcinoma in situ reaffirms proclivity for local recurrence even after more than 30 years of follow-up. Mod Pathol. 2015;28(5):662–9.

    Article  PubMed  Google Scholar 

  30. Stuart KE, Houssami N, Taylor R, Hayen A, Boyages J. Long-term outcomes of ductal carcinoma in situ of the breast: a systematic review, meta-analysis and meta-regression analysis. BMC Cancer. 2015;15:890.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  31. Inskip PD, Curtis RE. New malignancies following childhood cancer in the United States, 1973–2002. Int J Cancer. 2007;121(10):2233–40.

    Article  CAS  PubMed  Google Scholar 

  32. Buist DS, Abraham LA, Barlow WE, Krishnaraj A, Holdridge RC, Sickles EA, et al. Diagnosis of second breast cancer events after initial diagnosis of early stage breast cancer. Breast Cancer Res Treat. 2010;124(3):863–73.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Colditz GA, Kaphingst KA, Hankinson SE, Rosner B. Family history and risk of breast cancer: nurses’ health study. Breast Cancer Res Treat. 2012;133(3):1097–104.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet. 2001;358(9291):1389–99.

    Google Scholar 

  35. Lynch HT, Lynch JF. Breast cancer genetics in an oncology clinic: 328 consecutive patients. Cancer Genet Cytogenet. 1986;22(4):369–71.

    Article  CAS  PubMed  Google Scholar 

  36. Margolin S, Johansson H, Rutqvist LE, Lindblom A, Fornander T. Family history, and impact on clinical presentation and prognosis, in a population-based breast cancer cohort from the Stockholm County. Familial Cancer. 2006;5(4):309–21.

    Article  PubMed  Google Scholar 

  37. Lalloo F, Evans DG. Familial breast cancer. Clin Genet. 2012;82(2):105–14.

    Article  CAS  PubMed  Google Scholar 

  38. Sharif S, Moran A, Huson SM, Iddenden R, Shenton A, Howard E, et al. Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening. J Med Genet. 2007;44(8):481–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Mavaddat N, Barrowdale D, Andrulis IL, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer EpidemiolBiomark Prev. 2012;21:134–47.

    Article  CAS  Google Scholar 

  40. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998;62(3):676–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. King MC, Marks JH, Mandell JB, New York Breast Cancer Study G. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302:643–6.

    Article  CAS  PubMed  Google Scholar 

  43. Ziegler RG, Hoover RN, Pike MC, Hildesheim A, Nomura AM, West DW, et al. Migration patterns and breast cancer risk in Asian-American women. J Natl Cancer Inst. 1993;85(22):1819–27.

    Article  CAS  PubMed  Google Scholar 

  44. Thompson D, Easton D. The genetic epidemiology of breast cancer genes. J Mammary Gland Biol Neoplasia. 2004;9(3):221–36.

    Google Scholar 

  45. Diez O, Osorio A, Duran M, Martinez-Ferrandis JI, de la Hoya M, Salazar R, et al. Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects. Hum Mutat. 2003;22(4):301–12.

    Article  CAS  PubMed  Google Scholar 

  46. Mersch J, Jackson MA, Park M, Nebgen D, Peterson SK, Singletary C, et al. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer. 2015;121(2):269–75.

    Article  CAS  PubMed  Google Scholar 

  47. Thompson D, Duedal S, Kirner J, McGuffog L, Last J, Reiman A, et al. Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst. 2005;97(11):813–22.

    Article  CAS  PubMed  Google Scholar 

  48. Seal S, Thompson D, Renwick A, Elliott A, Kelly P, Barfoot R, et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet. 2006;38(11):1239–41.

    Article  CAS  PubMed  Google Scholar 

  49. Wong MW, Nordfors C, Mossman D, Pecenpetelovska G, Avery-Kiejda KA, Talseth-Palmer B, et al. BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer. Breast Cancer Res Treat. 2011;127(3):853–9.

    Article  CAS  PubMed  Google Scholar 

  50. Melhem-Bertrandt A, Bojadzieva J, Ready KJ, Obeid E, Liu DD, Gutierrez-Barrera AM, et al. Early onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer. 2012;118(4):908–13.

    Article  CAS  PubMed  Google Scholar 

  51. Honrado E, Benitez J, Palacios J. The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications. Mod Pathol. 2005;18(10):1305–20.

    Article  CAS  PubMed  Google Scholar 

  52. NCCN Guidelines version 1.2018. BRCA-related breast and/or ovarian cancer syndrome. http://www.nccn.org/professionals/physician_gls/pdf/

  53. Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004;23(7):1111–30.

    Article  PubMed  Google Scholar 

  54. Antoniou AC, Cunningham AP, Peto J, Evans DG, Lalloo F, Narod SA, et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer. 2008;98(8):1457–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Powell M, Jamshidian F, Cheyne K, Nititham J, Prebil LA, Ereman R. Assessing breast cancer risk models in Marin County, a population with high rates of delayed childbirth. Clin Breast Cancer. 2014;14(3):212–20.e1.

    Article  PubMed  Google Scholar 

  56. Armstrong J, Toscano M, Kotchko N, Friedman S, Schwartz MD, Virgo KS, et al. Utilization and outcomes of BRCA genetic testing and counseling in a National Commercially Insured Population: The ABOUT Study. JAMA Oncol. 2015;1(9):1251–60.

    Article  PubMed  Google Scholar 

  57. Domagala P, Hybiak J, Rys J, Byrski T, Cybulski C, Lubinski J. Pathological complete response after cisplatin neoadjuvant therapy is associated with the downregulation of DNA repair genes in BRCA1-associated triple-negative breast cancers. Oncotarget. 2016;7(42):68662–73.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Byrski T, Huzarski T, Dent R, Gronwald J, Zuziak D, Cybulski C, et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat. 2009;115(2):359–63.

    Article  CAS  PubMed  Google Scholar 

  59. Arun B, Bayraktar S, Liu DD, Gutierrez Barrera AM, Atchley D, Pusztai L, et al. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J ClinOncol. 2011;29(28):3739–46.

    Article  CAS  Google Scholar 

  60. Tutt A, Paul E, Kilburn L, Gilett C, Pinder S, Abraham J, et al. The TNT trial: a randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA 1/2 breast cancer. Cancer Res. 2014;75:S3–01.

    Google Scholar 

  61. Robson M, Goessl C, Domchek S. Olaparib for metastatic germline BRCA-mutated breast cancer. N Engl J Med. 2017;377(18):1792–3.

    Article  PubMed  Google Scholar 

  62. Ame JC, Spenlehauer C, de Murcia G. The PARP superfamily. BioEssays. 2004;26(8):882–93.

    Article  CAS  PubMed  Google Scholar 

  63. Gronwald J, Robidoux A, Kim-Sing C, Tung N, Lynch HT, Foulkes WD, et al. Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2014;146(2):421–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Narod SA, Brunet JS, Ghadirian P, Robson M, Heimdal K, Neuhausen SL, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet. 2000;356(9245):1876–81.

    Article  CAS  PubMed  Google Scholar 

  65. Metcalfe K, Lynch HT, Ghadirian P, Tung N, Kim-Sing C, Olopade OI, et al. Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2011;127(1):287–96.

    Article  CAS  PubMed  Google Scholar 

  66. Metcalfe K, Lynch HT, Ghadirian P, Tung N, Olivotto I, Warner E, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J ClinOncol. 2004;22(12):2328–35.

    Article  CAS  Google Scholar 

  67. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Le-Petross HT, Whitman GJ, Atchley DP, Yuan Y, Gutierrez-Barrera A, Hortobagyi GN, et al. Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer. Cancer. 2011;117(17):3900–7.

    Article  PubMed  Google Scholar 

  69. Tung N, Domchek SM, Stadler Z, Nathanson KL, Couch F, Garber JE, et al. Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nat Rev ClinOncol. 2016;13(9):581–8.

    Article  CAS  Google Scholar 

  70. Ramus SJ, Antoniou AC, Kuchenbaecker KB, Soucy P, Beesley J, Chen X, et al. Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Hum Mutat. 2012;33(4):690–702.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Brentnall TA. Cancer surveillance of patients from familial pancreatic cancer kindreds. Med Clin North Am. 2000;84(3):707–18.

    Article  CAS  PubMed  Google Scholar 

  72. Canto MI, Goggins M, Hruban RH, Petersen GM, Giardiello FM, Yeo C, et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. ClinGastroenterolHepatol. 2006;4(6):766–81. quiz 665

    Google Scholar 

  73. Kuerer H. Establishing a cancer genetics service. In: Kuerer’s breast surgical oncology. New York: McGraw-Hill Professional, Inc.; 2010.

    Google Scholar 

  74. MacDonald DJ, Blazer KR, Weitzel JN. Extending comprehensive cancer center expertise in clinical cancer genetics and genomics to diverse communities: the power of partnership. J Natl Compr Cancer Netw. 2010;8(5):615–24.

    Article  Google Scholar 

  75. Febbraro T, Robison K, Wilbur JS, Laprise J, Bregar A, Lopes V, et al. Adherence patterns to National Comprehensive Cancer Network (NCCN) guidelines for referral to cancer genetic professionals. GynecolOncol. 2015;138(1):109–14.

    Google Scholar 

  76. Levy DE, Garber JE, Shields AE. Guidelines for genetic risk assessment of hereditary breast and ovarian cancer: early disagreements and low utilization. J Gen Intern Med. 2009;24(7):822–8.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Biruni Univeristy School of Medicine, Protokol Yolu, Istanbul, Turkey

    Soley Bayraktar

  2. Department of Breast Medical Oncology and Clinical Cancer Genetics Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Banu Arun

Authors
  1. Soley Bayraktar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Banu Arun
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Banu Arun .

Editor information

Editors and Affiliations

  1. Breast Unit, San Raffaele University and Research Hospital, Milan, Italy

    Oreste Gentilini

  2. Dana–Farber Cancer Institute Department of Medical Oncology, Harvard Medical School, Boston, MA, USA

    Ann H. Partridge

  3. Geneva University Hospitals Swiss Group for Clinical Cancer Research (SAKK), Institute of Oncology of Southern Switzerland, Bellinzona, Switzerland

    Olivia Pagani

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Bayraktar, S., Arun, B. (2020). Establishing a Program for Young Women at High Risk for Breast Cancer. In: Gentilini, O., Partridge, A.H., Pagani, O. (eds) Breast Cancer in Young Women. Springer, Cham. https://doi.org/10.1007/978-3-030-24762-1_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-24762-1_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-24761-4

  • Online ISBN: 978-3-030-24762-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation